Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback

Executive Summary

US FDA recommends company start a new study of oral Fabry disease drug, to be designed using the agency's irritable bowel syndrome guidance for measuring efficacy in diarrhea.

Advertisement

Related Content

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
FDA Reversal Gives Amicus Renewed Hope For US Oral Fabry Launch
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Stockwatch: Awkward Developments Pricking J.P. Morgan Bubble
Stockwatch: A Biopharma Nativity Play
Oral Fabry Drug Clears CHMP, Amicus Sets Up 'Searchable Mutation' Website
Misreading FDA: Meeting Minutes Reality Sinks Amicus
Persistence Pays Off For Amicus: Positive Migalastat Data In Hand

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119595

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel